CELU - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים Celularity Inc.

Celularity Inc. is protected by a unique platform and strict FDA oversight, which limits competitor access. The development of allogeneic cells on a pipeline promises high margins despite R&D expenditures. The current YoY revenue growth rate on a TTM basis clearly demonstrates these trends, where the value of -58.10 serves as the baseline indicator. Patents for stem cell synthesis create an insurmountable barrier for new entrants.
פילוחי נתונים אנליטיים מרוכזים עבור Celularity Corp (CELU)

This indicator measures operational expansion dynamics by calculating the percentage change in revenue over a rolling twelve-month period. Analyzing this metric allows for the determination of commercial scaling sustainability and the risk of overvaluation. By examining the rolling year-over-year revenue growth chart, an investor assesses the efficiency of product monetization. For Celularity Inc. (CELU), this reflects the penetration rate of placental cell-based therapies into the regenerative medicine market. A positive trend would confirm the recognition of the therapy by medical insurers.